Enfin disponible en France, grâce à une étonnante formule France, 100% naturelle, vous pouvez maintenant dire stop à vos problèmes d’impuissance et à vos troubles de la virilité. Cette formule révolutionnaire agit comme un véritable achat levitra naturel. Ses résultats sont immédiats, sans aucun effet secondaire et vos érections sont durables, quelque soit votre âge. Même si vous avez plus de 60 ans !

Microsoft word - michael a. moore, md cv 02.25.05.doc

CURRICULUM VITAE

ADDRESS:
Office of Continuing Medical Education Danville Regional Medical Center 142 South Main Street Danville, Virginia 24541 Telephone: (434) 799-2178 E-mail: mam@learning-systems.net
PERSONAL INFORMATION:
EDUCATION:
University of North Carolina at Chapel Hill Chapel Hill, North Carolina BA (Chemistry) University of North Carolina School of Medicine Chapel Hill, North Carolina MD
POSTDOCTORAL TRAINING:
Straight Medicine Internship The Johns Hopkins Hospital Baltimore, Maryland Junior Assistant Residency in Medicine The Johns Hopkins Hospital Baltimore, Maryland Nephrology Fellowship: Hypertension Research and Clinical Nephrology The Johns Hopkins Hospital Baltimore, Maryland UNIFORMED SERVICE:
Major, U. S. Air Force Nephrologist, Keesler Medical Center Chief, Hypertension Service Biloxi, Mississippi
PROFESSIONAL LICENSURE:

SPECIALTY CERTIFICATION:
Hypertension Specialist, American Society of Hypertension
POSITIONS:
Clinical Professor of Internal Medicine (Nephrology) & Surgical Science Wake Forest University School of Medicine Winston-Salem, North Carolina Associate Clinical Professor of Medicine Department of Medicine, Division of Nephrology Bowman Gray School of Medicine Winston-Salem, North Carolina Clinical Professor of Medicine University of North Carolina School of Medicine Chapel Hill, North Carolina Family Healthcare Clinic Danville, Virginia Danville Urologic Clinic Danville, Virginia Assistant Clinical Professor of Medicine Department of Medicine, Division of Nephrology Bowman Gray School of Medicine Winston-Salem, North Carolina Assistant Professor of Medicine Department of Medicine, Division of Nephrology Bowman Gray School of Medicine Winston-Salem, North Carolina School of Health Services The Johns Hopkins Hospital Baltimore, Maryland
OTHER PROFESSIONAL APPOINTMENTS AND ACTIVITIES:
Committee for Continuing Education Bowman Gray School of Medicine Continuing Education Committee Danville Regional Medical Center Morbidity and Mortality Committee Danville Regional Medical Center Intensive Care Unit Committee Danville Regional Medical Center Continuing Medical Education Department of Medicine Danville Regional Medical Center Department of Medicine Danville Regional Medical Center Continuing Medical Education Danville Regional Medical Center Continuous Quality Improvement Committee Danville Regional Medical Center Danville Regional Health Foundation Board of Directors Clinical Research Unit Bowman Gray School of Medicine American Journal of the Medical Sciences Forsyth County Heart Association Hypertensive Screening, Education Member Hypertension Work Group North Carolina Heart Association Hypertension Work Group North Carolina Heart Association Danville-Pittsylvania County Academy of Medicine Public Relations Committee (1985) American Heart Association, Virginia Affiliate American Heart Association, Dallas, Texas American Heart Association Representative to the National High Blood Pressure Education Program Coordinating Committee for the National Institutes of Health Chairman, Long Range Planning Committee National High Blood Pressure Education Program Coordinating Committee for the National Institutes of Health Fourth Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure National High Blood Pressure Education Program NHLBI, National Institutes of Health Chairman Working Group on High Blood Pressure and Chronic Renal Failure National High Blood Pressure Education Program NHLBI, National Institutes of Health Medical Education Committee Medical Society of Virginia, Richmond, Virginia Member, Invited Participant NIH Workshop on Kidney Disease and Hypertension in Blacks National Institutes of Health Working Group to Develop Plan for Reducing Hypertensive End Stage Kidney Disease for the National High Blood Pressure Education Coordinating Committee Fifth Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure National High Blood Pressure Education Program National Institutes of Health Steering Committee Nephrology Center of Excellence School of Medicine University of North Carolina 1991 - 1993 External Facilitator/Lecturer 1993 Consensus Panel, Hypertension in Diabetes Mellitus Continuing Education Committee American Society of Hypertension Electronic Communication Project High Blood Pressure Education Program NHLBI, National Institutes of Health Consensus Panel, Diabetic Nephropathy American Diabetes Association San Francisco, California Subcommittee on Electronic Medical Education of the Education Committee Medical Society of Virginia Task Force on Establishing Networks Consortium of Southeastern Hypertension Centers Committee on Professional and Public Education Council for High Blood Pressure Research Sixth Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure National High Blood Pressure Education Program NHLBI, National Institutes of Health Reviewer Seventh Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure National High Blood Pressure Education Program NHLBI, National Institutes of Health Consultant to the National High Blood Pressure Education Program Consultant to Division of Adult Health Promotion, North Carolina Department of Environment, Health and Natural Resource, Raleigh, North Carolina Faculty Member/Contributing Author The Core Content Review of Family Medicine Columbus, Ohio Hypertension Management Protocol and Manual authored; served as expert resource for the Control of Hypertension in the Economically Challenged Patient. Division of Adult Health Promotion, State of North Carolina Hypertension Screening Component, Cardiovascular Project, Breast Cancer and Cervical Cancer Screening Program (funded through CDC grant). Authored teaching materials, instructed public health nurses, and served as expert resource. Division of Adult Health Promotion, State of North Carolina Consortium for Southeastern Hypertension Control
PROFESSIONAL MEMBERSHIPS:
American Federation for Clinical Research 1975-Present Johns Hopkins University Alumnae Association 1975-Present Johns Hopkins Medical and Surgical Association Danville-Pittsylvania County Heart Association Virginia Affiliate of the American Heart Association -Hypertension Committee Member, 1979-1980 Chairman, 1979-1980 -Medical and Community Programs, 1983 -Chairman, 1980-1982 -President Elect, 1981-1982 -President, 1982-1983 American Heart Association High Blood Pressure Research Council Committee of Professional and Public Education American Heart Association National Representative to the National High Blood Pressure Education Program NHLBI, National Institutes of Health Committee on Continuing Medical Education, 1994-1997 Medical Education Committee (CME Accreditation) National Association of Managed Care Physicians International Society of Hypertension in Blacks Consortium of Southeastern Hypertension Control Co-Chairman, Annual Meeting, 1996-Present Director Medical Education, 2002-Present 1994-Present Alliance for Continuing Medical Education
HONORS AND AWARDS:
George C. Thrasher Award Outstanding Performance in Psychiatry University of North Carolina School of Medicine Air Force Commendation Medal Outstanding Contributions to Hypertensive Management and Research U.S. Air Force Medical Center, Kessler Air Force Base Founders Award, Distinguished Leadership North Carolina Heart Association Achievement Recognition Award, Distinguished Service North Carolina Heart Association Teaching Excellence Award Bowman Gray School of Medicine Certificate of Appreciation Award Service in Advancing the Heart Program North Carolina Heart Association American Heart Association Special Award Energy, Enthusiasm, and Leadership in Program Development Virginia Heart Association Bronze Medallion, Meritorious Service Award Virginia Heart Association Silver Medallion, Distinguished Achievement Award Virginia Heart Association Silver Medallion, Meritorious Service Award Virginia Heart Association Certificate of Appreciation Award Service to the Hypertension Committee Virginia Heart Association Contributions to the Goals of the National High Blood Pressure Education Program National Heart, Lung and Blood Institute National Institutes of Health COSEHC Recognition Award Consortium of Southeastern Hypertension Control Awarded at 5th Annual Meeting, Atlanta, Georgia 2003 Community Service Award given to DRchip Founders: M. Moore, T. Motley, K. Plumb Awarded by the International Society of Hypertension in Blacks Awarded at the 2004 National Volunteer Leadership Conference Washington, D.C. 2004 Recognition Award by the Medical Society of Virginia For Development Enhanced Competency Medical Education 2004 House of Delegates Joint Resolution # 5038 Commending Dr. Michael A. Moore for his devotion to improving the health of COMMUNITY ACTIVITIES:
Chairman, Fund Raising Committee, 1983-1984 Chairman, Trust Committee, 1984-1985 Danville Public Schools Danville Development Council, Danville, Virginia American Cancer Association Board of Directors Danville, Virginia Danville Regional Health Systems Foundation Board of Directors Executive Committee of the Board of Directors Dan River Cardiovascular Health Initiative Program (DRchip) VISITING PROFESSORSHIPS:
Grand Rounds: Diuretic Induced Hypokalemia Eli Lilly Research Laboratories, Indianapolis, Indiana Weekly Staff Conference: End Stage Renal Disease 1991 Creighton University School of Medicine, Department of Internal Medicine Midwest Hypertension Research Institute, Omaha, Nebraska. Grand Rounds: “The National Tragedy of Hypertensive Kidney Failure” George Washington University, Physicians Assistant Program, Washington, DC. “Case Studies in Hypertension: New Treatment Guidelines” Churchill Hospital, Oxford University, Oxford, England. Renal Unit Conference: “The Epidemic of End Stage Kidney Disease in the United States” Queens Medical Center, University of Hawaii School of Medicine, Honolulu, Hawaii. “The Emerging Role of Angiotensin II in Hypertension” Westchester County Medical Center, Valhalla, New York. Grand Rounds: “The Emerging Role of Angiotensin II in Hypertension” Nephrology Seminar: “Preventing ESRD” St. Francis Medical Center, Honolulu, Hawaii. Grand Rounds: “Preventing End Queens Medical Center, University of Hawaii School of Medicine, Honolulu, Hawaii. Grand Rounds: “What Should Be the Goal of Hypertension Control?” San Juan Batista School of Medicine, San Juan, Puerto Rico. Grand Rounds: “The Role of Angiotensin II in Hypertension” Medical University of South Carolina. Graduate Class in Epidemiology: “The National High Blood Pressure Education Program—a New Approach to a Cardiovascular Epidemic” University of Hawaii School of Medicine, Honolulu, Hawaii. Internal Medicine Residency Program, 5 Cardiovascular Presentations
GRAND ROUNDS PRESENTATIONS:
Moore, MA. Outpatient Management of Hypertension. Grand Rounds, Johnson City Medical Center, Johnson City, Tennessee, June 20, 1986. Moore, MA. ESRD--A Virginia Epidemic. Nephrology Grand Rounds, Medical College of Virginia, Richmond, Virginia, September 16, 1992. Moore, MA. The ESRD Crisis. Preventive Medicine Grand Rounds, Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, April 13, 1993. Moore, MA. The JNCV Report. Grand Rounds, Hilo Hospital, Hilo, Hawaii, August 6, 1993. Moore, MA. Role of Angiotensin II in Hypertension. Medicine Grand Rounds, Brookdale Medical Center, Brooklyn, New York, November 10, 1995. Moore, MA. Role of Angiotensin II in Hypertension. Medicine Grand Rounds, St. Johns Medical Center, Queens, New York, November 10, 1995. Moore, MA. The Emerging Role of Angiotensin II in Hypertension. Grand Rounds, Riverside Medical Center with Teleconferencing to Rappahannock General Hospital, Newport News, Virginia, March 7, 1996. Moore, MA. Slowing the Increasing Incidence of End Stage Renal Disease. Medical Grand Rounds, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, April 16, 1996. Moore, MA. The Emerging Role of Angiotensin II in Hypertension. Medical Grand Rounds, Lincoln Medical Health Center, Bronx, New York, April 16, 1996. Moore, MA. The Role of Angiotensin II in Hypertension. Clinical Pharmacology Grand Rounds, New York Hospital, New York, New York, April 19, 1996. Moore, MA. The Role of Angiotensin II in Hypertensive and Diabetic Renal Disease. Grand Rounds, Allegheny Medical Center (formerly Hahnemann), Philadelphia, Pennsylvania, September 4, 1996. Moore, MA. A Targeted Approach to the Treatment of Hypertension. Grand Rounds, City Hospital, Martinsburg, West Virginia, February 6, 1997. Moore, MA. Angiotensin II Receptor Blockers. Medical Ground Rounds, Raritan Medical Center, Perth Amboy, New Jersey, April 22, 1997. Moore, MA. The Emerging Role of Angiotensin II in Hypertension. Grand Rounds, Putnam Hospital, Peekskill, New York, June 12, 1997. Moore, MA. Role of Angiotensin II in Hypertension. Family Medicine Grand Rounds, Duke University Medical Center, Durham, North Carolina, August 21, 1997. Moore, MA. What Should Be the Goal of Hypertension Control? Family Medicine Grand Rounds, Kaiser Permanente Medical Centers, Maui and Honolulu, Hawaii, October 30, 1997. Moore, MA. Emerging Role of Angiotensin II in Cardiovascular Disease. Grand Rounds, Chester County Hospital, West Chester, Pennsylvania, May 15, 1998. Moore, MA. The Emerging Role of Angiotensin in Hypertension. Department of Medicine Grand Rounds, Eastern Virginia School of Medicine, Norfolk, Virginia, January 20, 1999. Moore, MA. Clinical Controversies in Hypertension. Medical Grand Rounds, David Grant Medical Center, Travis Air Force Base, Fairfield, California, April 28, 1999. Moore, MA. The Role of Angiotensin II in Hypertension. Medical Grand Rounds, Mercy Healthcare System, Sacramento, California, April 30, 1999. Moore, MA. Strategies to Reduce the Increasing Incidence of End Stage Renal Disease. Medical Grand Rounds, MCP Hahnemann Medical University, Philadelphia, Pennsylvania, June 2, 1999. Moore, MA. Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, Trinity Lutheran Hospital, Kansas City, Missouri, March 22, 2000. Moore, MA. Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, Satilla Regional Medical Center, Tifton, Georgia, April 12, 2000. Moore, MA. Improving Hypertensive Patient Compliance. Medical Grand Rounds, Memorial Hospital, South Bend, Indiana, September 15, 2000. Moore, MA. Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, St. Joseph’s Medical Center, Baltimore, Maryland, October 25, 2000. Moore, MA. Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, Wright-Patterson Air Force Medical Center, Dayton, Ohio, October 31, 2000. Moore, MA. Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, George Washington University Medical Center, Washington, DC, November 6, 2000. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, Good Samaritan Hospital, Cincinnati, Ohio, November 14, 2000. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Department of Medicine Grand Rounds, Indiana University School of Medicine, Indianapolis, Indiana, January 24, 2001. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Grand Rounds, Community East Hospital, Indianapolis, Indiana, January 24, 2001. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, Columbus Regional Hospital, Columbus, Indiana, January 25, 2001. Moore, MA. Angiotensin II in Renal Disease. Grand Rounds, Department of Surgical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, April 17, 2001. Moore, MA. The Emerging Role of Angiotensin II in the Treatment of Hypertension. Grand Rounds, Nyack Hospital, Nyack, New York, May 21, 2001. Moore, MA. The Emerging Role of Angiotensin II in the Treatment of Hypertension. Grand Rounds, Community Medical Center, Toms River, New Jersey, May 24, 2001. Moore, MA. The Emerging Role of Angiotensin II in the Treatment of Hypertension. Medical Grand Rounds, Deborah Heart and Lung Center, Browns Mill, New Jersey, May 24, 2001. Moore, MA. Hypertension Update. Medical Grand Rounds, Wilson Memorial Regional Medical Center, Johnson City, New York, August 16, 2001. Moore, MA. New Treatment Options in the Management of Hypertension. Medical Grand Rounds, Lawrence General Hospital, Methuen, Massachusetts, October 24, 2001. Moore, MA. The Hypertension-Lipid Connection. Grand Rounds, Leonard Morse Hospital, Natick, Massachusetts, October 25, 2001. Moore, MA. The Diabetic Patient: Emerging Concepts. Medical Grand Rounds, St. Joseph Hospital, Towson, Maryland, October 26, 2001. Moore, MA. Outpatient Management of Hypertension. Medical Grand Rounds, Winchester Medical Center, Winchester, Virginia, November 21, 2001. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, Rex Hospital, Raleigh, North Carolina, April 18, 2002. Moore, MA. Strategies to Slow the Epidemic of ESRD. Medical Grand Rounds, Kuakini Medical Center, Honolulu, Hawaii, April 22, 2002. Moore, MA. Role of Angiotensin II in Cardiovascular Disease. Department of Medicine Grand Rounds, University of Hawaii School of Medicine, Queens Medical Center, Honolulu, Hawaii, April 23, 2002. Moore, MA. Strategies to Slow the Epidemic of ESRD. Medical Grand Rounds, Kaiser Permanente Medical Center, Honolulu, Hawaii, April 24, 2002. Moore, MA. Practical Approach to Managing the Hypertensive Diabetic Patient. Medical Grand Rounds, St Francis Hospital, Honolulu, Hawaii, April 25, 2002. Moore, MA. Methods to Improve Patient Compliance. Medical Grand Rounds, Tripler Army Medical Center, Honolulu, Hawaii, April 25, 2002. Moore, MA. Practical Approach to Managing the Hypertensive Diabetic Patient. Medical Grand Rounds, Queens Medical Center, New York, New York, April 26, 2002. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Grand Rounds, Allegheny General Hospital, Pittsburgh, Pennsylvania, May 8, 2002. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Grand Rounds, Sentara Virginia Beach General Hospital, Virginia Beach, Virginia, November 19, 2002. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Grand Rounds, Carolinas Medical Center, Mercy Hospital, Charlotte, North Carolina, November 22, 2002. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Grand Rounds, Allegheny Medical Center, Pittsburgh, Pennsylvania, September 10, 2003. Moore, MA. The Challenges of Improving Community Cardiovascular Health: A Virginia Approach— DRchip. Pediatric Grand Rounds, University of Virginia Health Science Center, Charlottesville, Virginia, June 3, 2004. Moore, MA. The Emerging Role of Angiotensin in Cardiovascular Disease. Akron General Hospital,
INVITED LECTURES
:
Moore, MA. Outpatient Management of Hypertension. Avery County Medical Society, Mountain AHEC, Montezuma, North Carolina, May 2, 1985. Moore, MA. The Highs and Lows of Blood Pressure. North Carolina Academy of Family Physicians, Mid-Summer Family Practice Digest, Myrtle Beach, South Carolina, July 6, 1985. Moore, MA. Dealing with Hypertensive Emergencies and Urgencies. Family Physicians Weekend, Raleigh, North Carolina, August 3, 1985. Moore, MA. Improving Patient Compliance. Eleventh Annual Southeastern Conference on High Blood Pressure Control, Tallahassee, Florida, October 30, 1985. Moore, MA. Advances and Challenges for the Community Treatment of Hypertension. Second Annual Conference of the North Carolina Coalition for High Blood Pressure Control, Raleigh, North Carolina, May 22, 1986. Moore, MA. Outpatient Management of Hypertension. Mountain AHEC Program, Spruce Pine, North Carolina, June 19, 1986. Moore, MA. The National High Blood Pressure Education Program of the United States. Keynote address at the launch of the Quebec National Heart Association, La Fondation du Quebec des Maladies du Coeur, Quebec, Canada, May 20, 1988. Moore, MA. Cost Considerations for the Management of End-State Renal Disease in the United States. Proceedings of the Workshop on Analysis of Cost and Benefit in Health Care, Bielefeld, West Germany, 1988. Moore, MA. (1) New Guidelines for the Treatment of Hypertension: Some Current Issues and (2) Non-Pharmacologic Treatment of Hypertension. University of North Carolina School of Medicine, Chapel Hill, North Carolina, May 6, 1989. Moore, MA. The Increasing Incidence and Cost of Hypertensive End Stage Kidney Disease. Medical Alumni Day, University of North Carolina School of Medicine, Chapel Hill, North Carolina, March 24, 1990. Moore, MA. Preventing Hypertensive ESRD. Preventive Cardiology Hypertension Conference, Yale University Medical Center, New Haven, Connecticut, May 10, 1990. Moore, MA. (1) Reducing Risk in the 1990s and (2) Hypertension and the Kidney. Western Pacific Conference, Hawaii State Department of Health, Honolulu, Hawaii, May 24, 1990. Moore, MA. Eggers P, Agadoa L, Porush JG. Hypertensive ESRD: Problem and Prevention. National High Blood Pressure and Cholesterol Control Conference, Washington, DC, April 5, 1991. Moore, MA. Hypertension and Chronic Renal Failure. The Welch Center for Preventive Medicine Hypertension Conference, The Johns Hopkins Hospital, Baltimore, Maryland, April 10, 1991. Moore, MA. Hypertension and Chronic Renal Failure. Sixth International Interdisciplinary Conference on Hypertension in Blacks, International Society of Hypertension in Blacks, Salvador, Brazil, August 3, 1991. Moore, MA. Preventing Chronic Renal Failure in the Hypertensive Patient. Cardiology Conference, Regional West Medical Center, Scottsbluff, Nebraska, October 12, 1991. Moore, MA. Physician-Patient Communication Seminar, Sponsored by the Virginia Reciprocal Underwriters, Inc., Wintergreen, Virginia, April 15, 1992. Moore, MA. Management of Hypertension with Chronic Renal Failure. Department of Internal Medicine Weekly Conference, St. Vincent's Hospital, Indianapolis, Indiana, May 6, 1992. Moore, MA. Preventing End Stage Kidney Disease. The Great Lakes Regional Conference on High Blood Pressure, Sponsored by the Indianapolis State Department of Health, Indianapolis, Indiana, May 7, 1992. Moore, MA. (1) Removing Barriers to Hypertensive Patient Compliance and (2) The Increasing Cost of End Stage Kidney Disease. Region VII Cardiovascular Risk Reduction Conference, Sponsored by the Health Departments of Kansas, Iowa, Missouri, and Nebraska, Topeka, Kansas, May 13, 1992. Moore, MA. Diabetic Kidney Disease: Recognition and Management. 14th Annual Health Care Professional Seminar, American Diabetes Association, Orlando, Florida, September 11, 1992. Moore, MA. Renal Considerations in Treating the Mature Hypertensive. Current Concepts in Managing the Mature Hypertensive Symposium, University of Colorado School of Medicine, Denver, Colorado, September 18, 1992. Moore, MA. Financial Management of the CME Program. Managing Your Continuing Education Program Symposium, Medical Society of Virginia, Norfolk, Virginia, October 29, 1992. Moore, MA. Long Range Strategies for the Primary Prevention of Hypertension. National High Blood Pressure Coordinating Committee Meeting, NHLBI, National Institutes of Health, Washington, DC, October 30, 1992. Moore, MA. (1) The Report of the 5th Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure and (2) ESRD: Recognition and Prevention Strategies. Annual Meeting of the National Organization for State Kidney Programs, Baltimore, Maryland, November 12, 1992. Moore, MA. (1) ESRD Crisis in America and (2) Evaluation of the Patient with Renal Insufficiency. Brookdale Medical Center, Brookdale, New York, January 26, 1993. Moore, MA. The ESRD Crisis in America. Preventive Medicine Conference, Albert Einstein School of Medicine, New York, New York, January 27, 1993. Moore, MA. The ESRD Crisis. College of Pharmacy, University of Illinois, Chicago, Illinois, April 13, 1993. Moore, MA. The JNCV Report. Renal Rounds, University of North Carolina School of Medicine, Chapel Hill, North Carolina, May 5, 1993. Moore, MA. The JNCV Report--Implications for Public Health. Staff Conference at the Division of Adult Medicine, Chronic Disease Branch, Department of Health, State of North Carolina, Raleigh, North Carolina, June 15, 1993. Moore, MA. (1) ESRD in Asian Americans and (2) Treatment of Hypertension in Diabetes Mellitus. Western Pacific Conference: New Frontiers in Heart Disease and Stroke, Hawaiian Department of Health, Honolulu, Hawaii, August 5, 1993. Moore, MA. ESRD: The Problem. Chairman, Symposium: ESRD a Southern Epidemic, Southern Medical Association Annual Meeting, New Orleans, Louisiana, October 28-29, 1993. Moore, MA. The JNCV Report. Family Medicine Plenary Session, Southern Medical Association Annual Meeting, New Orleans, Louisiana, October 28-29, 1993. Moore, MA. Update on the Year 2000 Objectives of the National High Blood Pressure Education Program. Fall Meeting, National High Blood Pressure Education Coordinating Committee, Milwaukee, Wisconsin, November 5, 1993. Moore, MA. Electrifying the Coordinating Committee. National High Blood Pressure Coordinating Committee, Bethesda, Maryland, April 15, 1994. Moore, MA. Angiotensin II Antagonists in Ischemic Nephropathy. Satellite Symposium: Role of Angiotensin II in Cardiovascular Pathology, National Scientific Sessions, American Heart Association, Dallas, Texas, November 13, 1994. Moore, MA. Hypertension and End Organ Disease. Regional Consultants Meeting, Merck Pharmaceutical Company, West Point, Pennsylvania, January 10, 1995. Moore, MA. Case Studies in Hypertension. Lynchburg Family Practice Residency Program, Lynchburg, Virginia, March 22, 1995. Moore, MA. Diabetic Hypertension Management in Minorities. North Carolina Conference on Diabetes Mellitus, State of North Carolina, Department of Environment, Health and Natural Resource, Division of Adult Health Promotion, Lumberton, North Carolina, March 29, 1995. Moore, MA. Role of Angiotensin in Hypertension. Nephrology Division Conference, Veteran’s Administration Medical Center, Miami, Florida, April 27, 1995. Moore, MA. Hypertension and Nephrosclerosis: Can Progressive Renal Failure be Prevented? Regional Conference, Special Issues in the Management of Hypertension, Cleveland Clinic/Morehead School of Medicine, Atlanta, Georgia, April 29, 1995. Moore, MA. The Role of Angiotensin II in Hypertension. Medical Conference, St. Francis Hospital, Honolulu, Hawaii, May 18, 1995. Moore, MA. The Role of Angiotensin II in Hypertension. Medical Conference, Hilo Hospital, Hilo, Hawaii, May 18, 1995. Moore, MA. (1) Preventing End Stage Kidney Disease and (2) Current Drug Therapy in Hypertension. American Heart Association, Hawaiian Chapter, Honolulu, Hawaii, May 18, 1995. Moore, MA. Preventing End Stage Renal Disease in Black Populations. Annual Meeting of the International Society of Hypertension in Blacks, St. Thomas, Virgin Islands, June 29, 1995. Moore, MA. Recommendations for the Detection and Evaluation of Hypertension. State of North Carolina Division of Adult Health Symposium, Charlotte, North Carolina, August 16, 1995. Moore, MA. Role of Angiotensin II in Hypertension. Family Medicine Residency Program, Carolinas Medical Center, Charlotte, North Carolina, August 22, 1995. Moore, MA. Role of Angiotensin II in Hypertension, Lynchburg Family Practice Residency Program. Consensus and Controversies in Hypertension Management, Medical Staff. Centura Health Systems, Lynchburg, Virginia, October 3, 1995. Moore, MA. Strategies to Prevent End Stage Kidney Disease. Division of Epidemiology, Albert Einstein College of Medicine, Bronx, New York, November 9, 1995. Moore, MA. Role of Angiotensin II in Hypertension. Cleveland County Medical Society, Chattanooga, Tennessee, November 14, 1995. Moore, MA. Renal Considerations in the Treatment of Hypertension. CME Symposium, University of Miami, Miami, Florida, November 18, 1995. Moore, MA. Role of Angiotensin II in Renal Disease. Endocrinology Division, Duke University Medical Center, Durham, North Carolina, December 4, 1995. Moore, MA. Case Studies in Hypertension. Family Medicine Residency Program, Carolinas Medical Center, Charlotte, North Carolina, December 13, 1995. Moore, MA. The Life Trial. Annual Meeting Consortium of Southeastern Hypertension Control, Research Triangle Park, North Carolina, August 14, 1996. Moore, MA. The Role of Angiotensin II in Hypertensive and Diabetic Renal Disease. Nephrology Rounds, Hershey Medical Center, Hershey, Pennsylvania, September 4, 1996. Moore, MA. Hypertensive Patient Compliance. Hypertension Seminar, Bowman Gray School of Medicine, Winston-Salem, North Carolina, September 23, 1996. Moore, MA. The Role of Angiotensin in Hypertensive and Diabetic Renal Disease. 1996 Annual Meeting of the Florida Society of Nephrology, Sannibell Island, Florida, October 5, 1996. Moore, MA. Co-Chairman, Symposium: Hypertension--Looking Ahead to the 21st Century. Southern Medical Association 1996 Annual Meeting, Baltimore, Maryland, November 20, 1996. Moore, MA. Strategies to Prevent End Stage Renal Disease. Southern Medical Association Annual Meeting, Baltimore, Maryland, November 22, 1996. Moore, MA. End Stage Renal Disease: Strategies to Slow the Increasing Incidence. Illinois Academy of Family Physicians, Medicine Today Lecture Series, Moline, Illinois, February 20, 1997. Moore, MA. Role of Angiotensin II in Renal Failure. John Deere Family Health Plan CME Program, Moline, Illinois, February 20, 1997. Moore, MA. The Role of Angiotensin II Receptor Blockade in Hypertension. Cedars Medical Center, Miami Beach, Florida, March 4, 1997. Moore, MA. Strategies to Reduce the Increasing Incidence of ESRD. Nephrology Conference, University of Virginia Heath Science Center, Charlottesville, Virginia, April 17, 1997. Moore, MA. The Emerging Role of Angiotensin II in Hypertension. Cardiology Conference, Deborah Heart and Lung Institute, Brown Hills, New Jersey, June 12, 1997. Moore, MA. Developing Presentation Skills. Halifax Regional Hospital, South Boston, Virginia, August 11, 1997. Moore, MA. Cardiovascular Disease in the Southeast. Doxazosin Investigators and Consultants Educational Exchange Meeting, Orlando, Florida, August 14, 1997. Moore, MA. Southeastern Hypertension: The Epidemic of End Stage Renal Disease, Cardiac Dysfunction and Renal Failure, Therapeutic Strategies for Preservation of Renal Function. Annual Meeting, Consortium for Southeastern Hypertension Control, Orlando, Florida, August 13-15, 1997. Moore, MA. Hypertension Therapy and the At-Risk Patient. American Heart Association, Western Pennsylvania District Seminar, Pittsburgh, Pennsylvania, August 23, 1997. Moore, MA. Strategies to Prevent Cardiovascular Disease in Hawaii. Hawaiian Medical Society Annual Meeting, Kona, Hawaii, October 31, 1997. Moore, MA. Hematuria in Childhood. Hawaiian Medical Society Annual Meeting, Kona, Hawaii, Moore, MA. The JNCVI: What’s New and What’s Old? Nephrology Conference, University of North Carolina School of Medicine, Chapel Hill, North Carolina, December 5, 1997. Moore, MA. Hypertension Control and End Stage Renal Disease. Medical University of South Carolina, Charleston, South Carolina, January 31, 1998. Moore, MA. Renal Protection: JNC VI. New Recommendations for the Management of Hypertensive Cardiovascular Disease Symposium, San Juan Batista School of Medicine, San Juan and Ponce, Puerto Rico, February 28, 1998. Moore, MA. Strategies to Slow the Epidemic of End Stage Renal Disease in the Southeast. SHAPP and Diabetes Annual Conference, Georgia State Health Department, Helena, Georgia, April 9, 1998. Moore, MA. Improving Hypertensive Patient Compliance with AT1 Blocking Drugs: The LETS Study. Effective Use of Drug Therapies in the Treatment of Hypertension and Vascular Disease Symposium, BGSM Hypertension Center, Asheville, North Carolina, April 17, 1998. Moore, MA. Efficacy of AT1 Blockers in Hypertension. American Society of Hypertension Annual Meeting Symposium, New York, New York, May 13, 1998. Moore, MA. Section Chair, The Clinical Course of Renal Disease in Hypertension. American Society of Hypertension Annual Meeting, New York, New York, May 15, 1998. Moore, MA. Improving Patient Compliance. Primary Care Clinical Conference, Nellis Air Force Base, Las Vegas, Nevada, July 23, 1998. Moore, MA. Emerging Concepts in First Line Therapy for the Treatment of Hypertension. Hypertension/Lipid National Consultants Meetings, Boston, Massachusetts, July 11, 1998; Baltimore, Maryland, August 8, 1998; Naples, Florida, August 14, 1998. Moore, MA. The Role of Angiotensin II in Hypertension. Cardiology Conference, Associacion Puertoriquerra del Corazon, San Juan, Puerto Rico, January 24, 1999. Moore, MA. Taking the Second Step in Hypertension Management. Centra Health System, Lynchburg, Virginia, February 2, 1999. Moore, MA. Renal Function in the Heart Failure Patient. International Conference, Rome University, Rome, Italy, February 5-7, 1999. Moore, MA. Hypertension Update. Ninth Annual Cardiology Symposium, Halifax Regional Medical Center, South Boston, Virginia, March 2, 1999. Moore, MA. Staying on Therapy: The Challenge of Disease Prevention. COSEHC Regional Consultant’s Meeting, Coral Gables, Florida, March 13, 1999. Moore, MA. The Role of Angiotensin II in Hypertension. 23rd Annual Internal Medicine Conference, Orlando Regional Health Care System, Orlando, Florida, March 16, 1999. Moore, MA. The Importance of Staying on Therapy. 63rd Japanese Circulation Society Conference, Tokyo, Japan, March 28, 1999. Moore, MA. The Role of Angiotensin II in Hypertension: Using ARBs in Hypertension. Weekly Clinical Pharmacology Conference, SKB Managed Care, Minneapolis, Minnesota, April 12, 1999. Moore, MA. Use of Angiotensin II Receptor Blockers in Hypertension. Clinical Pharmacology Conference, Humana Health System (HMO), Louisville, Tennessee, April 13, 1999. Moore, MA. The Decreasing Incidence of Hypertensive End Stage Renal Disease. National High Blood Pressure Education Program, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, April 16, 1999. Moore, MA. Strategies to Reduce the Increasing Incidence of End Stage Renal Disease. City wide nephrology conference, MCP Hahnemann University, Philadelphia, Pennsylvania, June 1, 1999. Moore, MA. The Role of Angiotensin II in the Managed Care of Hypertension. Merck National Managed Care Conference, New York, New York, June 4, 1999. Moore, MA. The Role of Angiotensin II in Atherosclerosis. Florida Lipid Association Annual Meeting, San Destin, Florida, July 10, 1999. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Conference, Schoolfield Barracks Medical Clinic, Honolulu, Hawaii, January 19, 2000. Moore, MA. Role of Angiotensin II in Hypertension. Regional External Medical Advisory Board, Consortium for Southeastern Hypertension Control, Destin, Florida, April 8, 2000. Moore, MA. Clinical Implications of Choosing Among the Angiotensin II Antagonists. Regional External Medical Advisory Board, Consortium for Southeastern Hypertension Control, Williamsburg, Virginia, April 24, 2000. Moore, MA. Resistant Hypertension. Renal Conference, Nephrology Division, University of Virginia Health Science Center, Charlottesville, Virginia, May 12, 2000. Moore, MA. Improving Hypertensive Patient Compliance. Regional External Medical Advisory Board Meeting of the Consortium for Southeastern Hypertension Control, Charlotte, North Carolina, May 17, 2000. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Noon Conference, Mercy Hospital, May 18, 2000. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Medical CME Conference, University of Tennessee Health Center, Knoxville, Tennessee, May 21, 2000. Moore, MA. The Emerging Role of Angiotensin II. Medical Conference, Olean General Hospital, Olean, New York, May 26, 2000. Moore, MA. Angiotensin II as the Driver in Renal Pathology. Medical Conference: Delivering on the Promise of Angiotensin II Antagonists, Ottawa, Canada, May 27, 2000. Moore, MA. Update on Angiotensin II. Medical Conference, 2000 Managed Care Consultants Meeting, Merck Pharmaceuticals, San Francisco, California, June 9, 2000. Moore, MA. Improving Hypertensive Patient Compliance. Noon Conference, Chester County Memorial Hospital, Chester, Pennsylvania, June 16, 2000. Moore, MA. Clinical Implications of Choosing Among the Angiotensin II Antagonists. Regional External Medical Advisory Board Meeting of the Consortium for Southeastern Hypertension Control, Amelia Island, Florida, July 22, 2000. Moore, MA. Improving Hypertensive Patient Compliance. Medical Conference: Annual Issues and Controversies in Managing Hypertension, Montreal, Canada, July 29, 2000. Moore, MA. Clinical Implications of Choosing Among the Angiotensin II Antagonists. Regional External Medical Advisory Board Meeting of the Consortium for Southeastern Hypertension Control, Charlottesville, Virginia, August 19, 2000. Moore, MA. The Role of Angiotensin II in Cardiovascular Disease. Annual Meeting of the Foundation for Better Health Care, Boston, Massachusetts, September 17, 2000. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Noon Conference, Dayton Heart Center, Dayton, Ohio, October 30, 2000. Moore, MA. Hypertension Update. 52nd Annual Meeting of the South Carolina Academy of Family Physicians, Hylton Head, South Carolina, November 11, 2000. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Medical Conference, Georgia Health Care Partners, Macon, Georgia, November 28, 2000. Moore, MA. (1) A New Paradigm for the Role of Angiotensin II in African American Hypertension and (2) Angiotensin II Antagonists and Congestive Heart Failure. 7th Annual Meeting of the Consortium for Southeastern Hypertension Control, Savannah, Georgia, November 30, 2000. Moore, MA. Evolving Strategies in the Treatment of Hypertension. National Meeting of the American Society of Health Systems Pharmacists, Las Vegas, Nevada, December 5, 2000. Moore, MA. ACEs and ARBs Should be First Step Therapy for Hypertension. 8th Annual National COSEHC Meeting, Charleston, South Carolina, August 21, 2001. Moore, MA. New Treatment Strategies for Diabetic Nephropathy. Puerto Rico Society of Nephrology and Hypertension Annual Scientific Meeting, San Juan Puerto Rico, October 28, 2001. Moore, MA. The Emerging Role of Angiotensin II in the Treatment of Hypertension. Current Concepts in Cardiovascular Management Symposium, University of Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, November 3, 2001. Moore, MA. Renal Protection in the Diabetic and Hypertensive Patient. Virginia Academy of Family Physicians, Winter Family Practice Weekend, Wintergreen, Virginia, February 2, 2002. Moore, MA., Ferrario, C.M., Yunis, C. Wake Forest University School of Medicine, Winston-Salem, North Carolina. A New Approach to Community Based Cardiovascular Health Care Prevention Program: The COSEHC Cardiovascular Centers of Excellence. 2002 National Cardiovascular Health Conference, Washington, DC, April 11, 2002. Moore, MA. The Role of Angiotensin II in Renal Disease. Department of Surgical Sciences Grand Rounds, Wake Forest University School of Medicine, Winston-Salem, North Carolina, April 17, 2002. Moore, MA. Behavioral Barriers to Optimal Risk Factor Control. Plenary Session, Annual Meeting of the International Society for Hypertension in Blacks, Miami, Florida, June 12, 2002. Moore, MA. (1) Tailoring Lifestyle Modifications to the Southern Hypertensive: What Does the Evidence Show? (2) Vascular Biology: Should it Determine Our Choice of Antihypertensive Therapy? (3) Angiotensin Receptor Blockers. Sixth Annual Conference on Hypertension, Southern Medical Association, Wild Dunes Resort, Charleston, South Carolina, June 28-30, 2002. Moore, MA. (1) Vascular Effects of Antihypertensive Drugs; (2) Interruption of the Renin Angiotensin –Aldosterone System (RAAS) in the Prevention and Treatment of Renal Disease and Proteinuric States, (3) Angiotensin II Receptor Blockers: The Masters’ Debate. 10th Annual Meeting Consortium for Southeastern Hypertension Control, Savannah, Georgia, October 17-19, 2002. Moore, MA. Model of Minority CVD Prevention: DRchip. Second Annual Primary Care Conference, NHLBI / Morehouse University School of Medicine, Atlanta, Georgia, November 1, 2002. Moore, MA. Hypertension Management in the Type 2 Diabetic Patient. 2002 Annual Diabetes Symposium, Valdosta, Georgia, November 2, 2002. Moore, MA. Clinical Trials with Angiotensin II Antagonists. NIH Program Project Grant Weekly Conference. Hypertension and Vascular Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, December 2, 2002. Moore, MA. Hypertension Update. The Winter Meeting of the North Carolina American Family Physician Association, Asheville, North Carolina, December 7, 2002. Moore, MA. Benefit of Blocking the RAA System in the Type 2 Diabetic Patient. COSEHC Regional CME Conference, Norfolk, Virginia, February 8, 2003. Moore, MA. Cardiovascular Disease: Diagnosis and Treatment. United Health Care Systems, TIV Educational Services, Houston, Corpus Christi, Dallas, Austin, and Dallas, Texas, Moore, MA. Lessons Learned From Clinical Trials: How Best to Protect the Kidney. Expert in Hypertension Series: Focus on Lifestyle, Renin-Angiotensin Systems Blockade, and Clinical Outcome Trials, Carolinas Chapter, American Society of Hypertension, Charlotte, North Carolina, April 5, 2003. Moore, MA. Diabetes and the Kidney. New Frontiers in Cardiovascular Disease Management, Consortium for Southeastern Hypertension Control Satellite Symposium, Inter-American Society of Hypertension, San Antonio, Texas, April 29, 2003. Moore, MA. Management of Hypertension for Controlling Cardiovascular Risk Factors. Getting Good Hypertension and Lipid Management into Communities, a COSEHC Regional CME Conference, San Antonio, Texas, May 1, 2003. Moore, MA. Hypertension in the Renal Patient: What Do Clinical Trials Tell Us? Hypertension Update, Southern Medical Association, Myrtle Beach, South Carolina, June 27, 2003. Moore, MA. Microalbuminuria--Should It Be Part of the Baseline Evaluation of Hypertension? Hypertension Update, Southern Medical Association, Myrtle Beach, South Carolina, June 28, 2003. Moore, MA. The Emerging Role of Angiotensin II in Cardiovascular Disease. Tenth Annual Cardiology Symposium, Oakwood Annapolis Hospital CME Program, Detroit, Michigan, July 23, 2003. Moore, MA. New Strategies for Renal Protection. COSEHC Regional CME Symposium, Norfolk, Virginia, July 26, 2003. Moore, MA. The Heart at Risk. Georgia CME Institute, Atlanta, Georgia, July 29, 2003. Moore, MA. (1) Metabolic Syndrome and Implications for the Kidney, and (2) COSEHC, The First Ten Years. COSEHC 10th Annual Scientific Sessions, Coral Gables, Florida, October 16, 2003. Moore, MA. Renal Disease in the Diabetic Patient. 2003 Annual Diabetic Symposium, South Georgia Medical Center, Valdosta, Georgia, October 25, 2003. Moore, MA. Case Studies in Global Cardiovascular Management. Global Management of Cardiovascular Disease, COSEHC Regional Symposium, Lexington, Kentucky, November 12, 2003. Moore, MA. Managing the Acute Coronary Syndrome. TIV Educational Services CME Symposium, Charleston, Spartanburg, and Columbia, South Carolina, November 13, 18, and 19, 2003. Moore, MA. COSEHC Centers of Excellence. Tenth Anniversary of the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, November 17, 2003. Moore, MA. Controlling Hypertension. Fourth Annual Cardiovascular Management Conference, Kaleida Health System, University of Buffalo School of Medicine, Buffalo, New York, November 22, 2003. Moore, MA. Can Diabetic ESRD Be Prevented? Global Management of Cardiovascular Disease, COSEHC Regional Symposium, Forest General Hospital, Hattiesburg, Mississippi, December 4, 2003. Moore, MA. The Emerging Role of Angiotensin in Cardiovascular Disease. Nephrology Conference, The Mayo Clinic, Minneapolis, Minnesota, March 3, 2004. Moore, MA. Management of Hypertension: Rationale for Combination Therapy. Clinical Conference, Michigan State University for Medical Studies, Kalamazoo, Michigan, April 15, 2004. Moore, MA. Evaluation of the Hypertensive Patient. American Society of Hypertension, Carolinas Chapter Symposium, Charlotte, North Carolina, April 17, 2004. Moore, MA. The Role of Angiotensin II in Cardiovascular Disease. Society of Army Physician Assistants, 2004 Refresher Course, Fayetteville, North Carolina, April 28, 2004. Moore, MA. JNC 7 Update. Keynote Address, Sentara Eighth Annual Conference on Care Effectiveness, Williamsburg, Virginia, May 8, 2004. Moore, MA. Evaluating the Hypertensive Patient; Initial Treatment of the Hypertensive Patient; and Treatment of Hypertension with Compelling Indications. American Society of Hypertension, Carolinas Chapter Symposium, Rural Hypertension Outreach Program, Wilmington, North Carolina, May 15, 2004. Moore, MA. Microalbuminuria. Hypertension, Hyperlipemia, and Stroke Symposium, New York Academy of Medicine, New York, New York, May 17, 2004. Moore, MA. Evaluating the Hypertensive Patient; Initial Treatment of the Hypertensive Patient; and Treatment of Hypertension with Compelling Indications. American Society of Hypertension, Carolinas Chapter Symposium, Rural Hypertension Outreach Program, Hendersonville, North Carolina, Moore, MA. Evaluating the Hypertensive Patient; Initial Treatment of the Hypertensive Patient; and Treatment of Hypertension with Compelling Indications. American Society of Hypertension, Carolinas Chapter Symposium, Rural Hypertension Outreach Program, Greenville, North Carolina, June 12, 2004. . Moore, MA. Evaluation of the Hypertensive Patient. American Society of Hypertension, Carolinas Chapter Symposium, Chapel Hill, North Carolina, June 19, 2004. Moore, MA. Hypertension in the Renal Patient. Southern Medical Association, Eighth Annual Hypertension Meeting, Hilton Head, South Carolina, June 25, 2004. Moore, MA. DRchip: The challenge of improving community cardiovascular health: A southside Virginia approach. The Virginia Governor’s Healthy Virginia Summit, Charlottesville, VA, November 29, 2004. Moore, MA. Strategies to Improve Hypertension Control. Annual Meeting Virginia Academy of Family Physicians, Wintergreen, VA, February 5, 2005.
VIDEO PRESENTATIONS:
Moore, MA. CME VIDEO. End Stage Renal Disease: Preventing Dialysis Through Early Recognition and Treatment. The Network for Continuing Medical Education, One Harmon Plaza, Secaucus, New Jersey. Film distributed to subscriber libraries and other teaching institutions, January, 1991. Moore, MA. Epidemiology and Detection of Hypertension. North Carolina Public Health Nurses state-wide video conference for Cardiovascular Project, Breast Cancer and Cervical Cancer Screening Program, North Carolina Department of Health, Chapel Hill, North Carolina, October 23, 1995.

SELF-ASSESSMENT TEACHING:
Moore, MA, contributing author, Comprehensive Family Medicine Managed Care Self-Assessment Program (CCMC-SAP). Health Care Associates, Philadelphia, Pennsylvania, 1996. Moore, MA, contributing author, Comprehensive Chiropractic Managed Care Self-Assessment Program (CCMC-SAP). Health Care Associates, Philadelphia, Pennsylvania, 1996. Moore, MA, Chronic Renal Failure. Edition No. 155, Home Study Self-Assessment Program. American Academy of Family Physicians, Kansas City, Missouri, April, 1992.
ABSTRACT ORAL PRESENTATIONS:
Cogburn, BE, Moore, MA, Phillippi, PJ. Efficient Management of Hypertensive Outpatients Utilizing Physician Extenders. Presented at the USAF Regional Meeting of the American College of Physicians, San Antonio, Texas, February, 1976. Moore, MA, Miller, JE, Mooney, LR. Reversible Acute Renal and Pulmonary Failure from Myoglobinuria. Presented at the 1976 Air Force Society of Physicians, Williamsburg, Virginia, 1976. Moore, M, Starling, JF, Hall, J. Hypertensive Patient Compliance in a Private Clinic. Presented at the Virginia Regional Meeting of the American College of Physicians, Williamsburg, Virginia, February 27, 1982. Baker, WB, Maddux, D, Pratt, J, Starling, JS, Moore, MA, Maddux, F. Missouri Swan Neck Catheters: Coiled vs. Straight--a Prospective 18-Month Study. Presented at the XII Annual Peritoneal Conference, Seattle, Washington, 1992. Moore, MA, Starling, S, Baker, WB, Maddux, FA, Maddux, D. Inadequate Patient Education and Late Referral for Dialysis for African American Patients with End Stage Kidney Disease. Presented at the International Society of Hypertension in Blacks Annual Meeting, St. Thomas, Virgin Islands, June 28, 1995. Moore, M.A, Motley, T., Plumb, K. Case Managers for Evidence-Based Outcomes for Continuing Medical Education Improvement. 2002 National Cardiovascular Health Conference, Washington, DC, April 11, 2002. Plumb, K, Motley, T, Moore, MA. DRchip's Community Action Plan Mobilization of Community Resources to Reduce Cardiovascular Disease. 2002 National Cardiovascular Health Conference, Washington, DC, April 11, 2002. Plumb, K, Motley, T, Moore, MA. Public Health Nurse's Approach to Reducing Cardiovascular Disease--Cohort of Middle School Children. 2002 National Cardiovascular Health Conference, Washington, DC, April 11, 2002. Moore, MA, Motley, T, Plumb, K, Smith, L. DRchip, EDUC, and COSEHC: A Triple Public Health Strategy to Reduce Mortality in a High Cardiovascular Risk Community. Annual Meeting of the American Society of Hypertension, New York, New York, May 18, 2002.
Lackland, D, Moore, MA, Egan B, Ferrario CM. The Impact of Hypertension and Diabetes
on the Epidemic of Southeastern Renal Disease. Presented at XV Inter-American Society
of Hypertension Annual Meeting, San Antonio, Texas, April 29, 2003.

ABSTRACT POSTER PRESENTATIONS
:
Moore, M, Volosin, K, Harter, C, et al. First Voided Urine Sodium/Creatinine Ratio as a Valid Indication of Previous Day's Salt Intake. Presented at the National High Blood Pressure Conference, Los Angeles, California, April 1978. Moore, M, Burgess, R, Volosin, K, Chandler T. Age Related Non-compliance in a Model Hypertension Clinic. Presented at National High Blood Pressure Conference, Washington, DC, April 6, 1979. Moore, M, Burgess, R, Volosin, K. Spot Urinary Sodium/Creatinine Ratio Predicts Previous Day's 24-hour Sodium Excretion in Young Essential Hypertensives. Presented at the National High Blood Pressure Conference, Washington, DC, April 6, 1979. Baker, WB, Maddux, DW, Maddux, FM, Moore, MA, Starling, JS. The Use of Laparoscopy for Evaluation of Mechanical Problems Associated with Peritoneal Dialysis. Presented at the 11th Annual Conference of Peritoneal Dialysis, Nashville, Tennessee, February 7, 1991. Moore, MA, Starling, JS, Baker, WB, Maddux, DW, Maddux, FW. No J Point Distribution of Diastolic Blood Pressure and Cardiac Mortality during Chronic Hemodialysis. Presented at 1991 Annual Meeting American Society of Hypertension, New York, New York. Am J Hypertens 1991;4:346. Moore, MA, Eggers, P. Minorities Have the Highest Incidence of End Stage Kidney Disease. Presented at the Inter-American Society of Hypertension, La Jolla, California, April 27, 1993. Moore, MA, Grazdick, LP, Edelman, AL, Vrecenak, LA, Demopoulos, PT, DeLucca, JT, Flaherty, JT, for the LETS Investigators. Losartan Effectiveness and Tolerability (LET) Study. Presented at Annual Meeting of American Society of Hypertension, New York, New York, May 1998. Am J Hypertens 1998;11:104A. Moore, MA. Case Managers for Evidence-Based Outcomes for CME. Annual Meeting of the American Society of Hypertension, New York, New York, May 18, 2002. ABSTRACTS:
Moore, MA, Volosin, K, Burgess, R, Buckalew, V. Estimation of 24-hour sodium excretion (UnaV) by a spot urinary sodium/creatinine ratio. Kidney Int 1970;12:504. Moore, MA, Horvath, J, Nichols, W, Siebens AW, Walker WG. Transpulmonary conversion of angiotensin I (AI) to angiotensin II (AII) in vivo. Clin Res 1973;21:439. Walker, WG, Horvath, JS, Moore, MA, Russell, KP, Conti, CR, Mitch, WE. Pulmonary generation and peripheral uptake of endogenous angiotensin II (AII) in man. Clin Res 1973;21:719. Moore, MA, Horvath, JS, Walker, WG. Angiotensin II and renin responses to Na restriction and Na deple tion in normal subjects. Circulation 1973;47/48(suppl IV):IV-70. (Presented) Horvath, JS, Moore, MA, Russell, RP, Walker, WG. Arterial and venous angiotensin II and plasma renin activity (PRA) in mild hypertension. Circulation 1973;48(suppl IV):IV-32. Horvath, JS, Moore, MA, Russell, RP, Walker, WG. Abnormalities of plasma renin activity (PRA), arterial and venous angiotensin II (A11) in essential hypertension. Aust N Z J Med 1974;4:422. Cooke, CR, Horvath, JS, Moore, MA, Bledsoe, T, Walker, WG. Adrenal cortical response to acute volume depletion in anephric man. J Clin Invest 1974;53:17A. Cooke, CR, Whelton, PK, Moore, MA, Bledsoe, T, Walker, G. Separation of diurnal variation of plasma aldosterone and cortisol by bilateral nephrectomy. Kidney Int 1974;6:33A. Walker, WG, Horvath, JS, Moore, MA, Russell, RP. Inverse relation of plasma renin activity (PRA) to diastolic blood pressure in essential hypertension. Sixth International Congress of Nephrology, Florence, Italy. Abstracts of Free Communications # 459, June 8-12, 1975. Moore, MA, Phillippi, PJ. Renin and renal cell carcinoma with arteriovenous malformation and hypertension. Kidney Int 1976;9:45. Moore, MA, Merson, MH, Charache, P, Shepard, RH. Observations on the characteristics and mortality of community acquired bacterial pneumonia in an urban population. Clin Res 1976;24:7A. Moore, MA, Tyras, D. Increased renin generation from experimental renal arteriovenous fistula (RAVF). Kidney Int 1976;10:534. Moore, MA, Miller, JE, Mooney, LR. Reversible acute renal and pulmonary failure from myoglobinuria. Clin Res 1976:38A. Moore, M, Volosin, K, Burgess, R, et al. Estimation of 24-hour sodium excretion (Una/Cr) by a spot urinary sodium creatinine ratio. Kidney Int 1977;12:504. Moore, M, Phillippi, P, Cooke, C. Age related progressive renin suppression in essential hypertension. Clin Res 1978;26:23A. Kahl, F, Moore, M. Incidence of abnormal blood pressures in 11th grade students in North Carolina. Clin Res 1978;26:13A. Moore, M, Burgess, R, Harper, C, et al. Hypertension management courses to train registered nurses (RN) as hypertension therapists (HT) and to educate physicians in methods for utilizing physician extenders in outpatient hypertension management. Prev Med 1978;7:116. Moore, M, Volosin, K, Harper, C, et al. First voided urine sodium/creatinine ratio as a valid indicator of previous day's salt intake. Prev Med 1978;7:116. Moore, M, Heise, E, Goodman, H, Volosin, K, Buckalew, V. Pedigree analysis of HLA blood group markers in essential hypertension. Clin Res 1978;26:366A. Cooke, C, Whelton, P, Moore, M, Bledsoe, T, Gann, D, Walker, W. Aldosterone and cortisol response to acute volume depletion in anephric man. Kidney Int 1978;14:723. Moore, M, Burgess, R, Volosin, K, Chandler, T. Age related non-compliance in a model hypertension clinic. Prev Med 1979;8:199. Moore, M, Volosin, K, Burgess, R. Hypertension management by a lone physician. Prev Med 1979;8:199. Moore, M, Burgess, R, Volosin, K. Spot urinary sodium/creatinine ratio predicts previous day's 24-hour sodium excretion in young essential hypertensives. Prev Med 1979;8:200. Volosin, KJ, Moore, M, Burgess, R, Buckalew, V. Acute effects of oral caffeine ingestion on blood pressure. Prev Med 1980;9. Moore, M, Starling, JF, Hall, J. Hemoperfusion for perphenazine and amitriptyline overdose. Clin Res 1981;29:275A. Moore, M, Starling, JF, Hall, J. Hypertensive patient compliance in a private clinic. Va Med Q 1982;109:113-114. Caruana, RJ, Pearson, FC, Burkart, J, Moore, M, Dubczak, J, Weary, M, Bohon, J. Serum levels of limulus amebocyte lystae reactive material (LAL-RM) in chronic hemodialysis patients. Kidney Int 1986;29:211. Moore, MA, Hall, JW, Starling, JF, Baker, WB. Reversible nonoliguric renal insufficiency due to a new diuretic combination-maxzide. Kidney Int 1986;29:198. Starling, JF, Moore, MA, Hall, JW, Baker, WB. Complications from subclavian hemodialysis catheters. Kidney Int 1986;29:226. Moore, MA, Eggers, P. The ever increasing incidence and cost of hypertensive end stage renal disease in the United States. Proceedings of the National High Blood Pressure Control Conference, Orlando, Florida, May 1988. Baker, WB, Pratt, J, Stone, K, Hall, J, Moore, M, Starling, JS. Peritonitis and exit site infection rates using single cuff Tenckhoff Missouri swan neck peritoneal catheters. Proceedings IX Annual Peritoneal Conference, Dallas, Texas, 1989. Baker, WB, Maddux, DW, Maddux, FM, Moore, MA, Starling, JS. The use of laparoscopy for evaluation of mechanical problems associated with peritoneal dialysis. Proceedings of the XI Annual Peritoneal Dialysis Conference, New Orleans, Louisiana. Peritoneal Dialysis International 1991;11:16. Moore, MA, Starling, JF, Baker, WB, Maddux, F, Maddux, D. Inadequate patient education and late referral for dialysis for African American patients with end-stage kidney disease. The Tenth International Interdisciplinary Conference on Hypertension in Blacks, June 24-29, 1995. Moore, MA, Edleman, J, Vrecenak, A, Demopoulis, L, Gazdick, L, Flaherty, JT, and the LETS Investigators. Losartan effectiveness and tolerability study. Am J Hypertens 1998;11 (Number 4, Part 2): 104A. JOURNAL ARTICLES:
Walker, WG, Horvath, JS, Moore, MA, Russell, RP, Conti, CR, Mitch, WE. Pulmonary generation and
peripheral uptake of endogenous angiotensin II in man. Trans Assoc Am Physicians 1973;86:226-236.
Cooke, CR, Horvath, JS, Moore, MA, Bledsoe, T, Walker, WG. Modulation of plasma aldosterone concentration by plasma potassium in anephric man in the absence of a change in potassium balance. J Clin Invest 1973;52:3028-3032. Walker, WG, Horvath, JS, Moore, MA, Russell, RP. Some observations on arterial and venous levels of angiotensin II in man. Trans Am Clin Climatol Assoc 1973;85:151-162. Walker, WG, Horvath, JS, Moore, MA, Whelton, P, Russell, RP. Relation between plasma renin activity, angiotensin, aldosterone and blood pressure in mild untreated hypertension. Circ Res 1976;38:470-476.
Walker, WG, Moore, MA, Horvath, JS, Whelton, PK. Arterial and venous angiotensin II in normal subjects. Relation to renin activity and plasma aldosterone concentration, and response to posture and volume changes. Circ Res 1976;38:477-483. Moore, MA, Phillippi, PJ. Clinical use of plasma renin activity. Mil Med 1977;142:611-612. Moore, MA, Merson, MH, Charache, P, Shepard, RH. The characteristics and mortality of outpatient-acquired pneumonia. Johns Hopkins Med J 1977;140:9-14. Moore, MA, Phillippi, PJ. Reversible renal hypertension secondary to renal arteriovenous fistula and renal cell carcinoma. J Urol 1977;117:246-247. Moore, MA. Hypertension in the ambulatory patient. Am Fam Physician 1977;16:188-197. Harper, RN, Moore, MA, Marr, MC, Watts, LE, Hutchins, PM. Arteriolar rarefaction in the conjunctiva of human essential hypertension. Microvasc Res 1978;16:369-372. Moore, MA. Practical management of chronic renal failure. Am Fam Physician 1979;19:158-164. Cooke, CR, Whelton, PK, Moore, MA, Caputo, RA, Bledsoe, T, Walker, WG. Dissociation of the diurnal variation of aldosterone and cortisol in anephric subjects. Kidney Int 1979;15:669-675. Moore, MA. Hypertensive emergencies. Am Fam Physician 1980;21:141-146. Jennette, JC, Ferguson, AL, Moore, MA, Freeman, DG. IgA nephropathy associated with seronegative spondylarthropathies. Arthritis Rheum 1982;25:144-149. Moore, MA. Step-care approach to improving hypertensive patient compliance. Am Fam Physician 1982;26:155-160. Cooke, CR, Gann, DS, Whelton, PK, Hsu, TH, Bledsoe, T, Moore, MA, Walker, WG. Hormonal responses to acute volume changes in anephric subjects. Kidney Int 1983;23:71-78. Moore, MA. Current management of hypertension. Am Fam Physician 1985;32:129-136. Heise, ER, Moore, MA, Reid, QB, Goodman, HO. Possible association of MN locus haplotypes with essential hypertension. Hypertension 1987;9:634-640. Moore, MA. Improving compliance with antihypertensive therapy. Am Fam Physician 1988;37:142-148. 1988 Joint National Committee. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988;148:1023-1038.
Moore, MA. Cost considerations for the management of end stage renal disease in the United States. Proceedings of The Workshop on Analysis of Cost and Benefit in Health Care, 1988, Bielefeld, West Germany. Moore, MA, Blythe, WB, Cutler, JA, Eggers, PW, Grim, CE, Nickey, WA, Perry, HM, Porush, JG, Shulman, NB, Vidt, DG, Walker, WG, FitzSimmons, SC, Horan, MJ, Rocella, EK, Thom, TJ. NHLBI working group report on hypertension and chronic renal failure. Arch Intern Med 1991;151:1280-1287. Moore, MA, Porush, JG. Hypertension and renal insufficiency: recognition and management. Am Fam Physician 1992;45:1248-1256. 1992 Joint National Committee. The 1992 Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-183. Moore, MA. End stage kidney disease: increasing incidence in Virginia. Va Med Q 1993;120:99-103. Consensus Panel: Hypertension in Diabetes. Diabetes Care 1993;16:1394-1401. Gillis, BP, Caggiula, AW, Jones, FL, Maurer, E, Meehan, RM, Yamamoto, ME, and the Modification of Diet in Renal Disease Study Group. (Moore MA, MDRD Investigator) Features of the nutrient database and analysis system for the Modification of Diet in Renal Disease Study. Controlled Clinical Trials 1994;15:44-58. Klahr, S, Levey, AS, Beck, GJ, Caggiula, AW, Hunsicker, L, Kusek, JW, Striker, G. For the Modification of Diet in Renal Disease Study Group. (Moore MA, MDRD Investigator) The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-884. Carter, BL, Frohlich, ED, Elliot, WJ, Moore, MA, Mann, RJ, Roberts, RW. Selected factors that influence responses to antihypertensives: choosing therapy for the uncomplicated patient. Arch Fam Med 1994;3:528-536. Consensus Panel. Diabetic nephropathy. Diabetes Care 1994; 17:1357-1361. Moore, MA. End stage renal disease: a southern epidemic. South Med J 1994;87:1013-1017. Moore, MA. Hypertension in renal insufficiency. Contemp Intern Med 1995;7:10-20. Mazmanian, P, Mazmanian, P, Moore, MA. Evaluation-based accreditation alternative approach to regulating CME providers. J Contin Educ Health Prof 1995;16 (2):112-116. National High Blood Pressure Education Program Working Group. Reports on chronic renal failure and renovascular hypertension. Arch Intern Med 1996;156:1938-1947. Lackland, DT, Moore, MA. Hypertension related mortality and morbidity in the Southeast. South Med J 1996;90:191-198. Hall, WD, Ferrario, CM, Moore, MA, Hall, JE, Flack, JM, Cooper, W, Simmons, JD, Egan, BM, Lackland, DT, Perry, M, Roccella, EJ. Hypertension related morbidity and mortality in the southeastern United States. Am J Med Sci 1997;313(4):195-209. Sixth Joint National Committee. The Sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2448. Moore, MA, Epstein, M, Agadoa, L, Dworkin, L. Current strategies in the management of hypertensive renal failure. Arch Intern Med 1998;159:23-28. Moore, MA, Edelman, JM, Gazdick, LP, Vrecenak, AJ, DeLucca, P, Flaherty, JT, for the LET Investigators. Choice of initial antihypertensive medication may influence the extent to which patients stay on therapy: a community-based study of a losartan-based regimen vs usual care. High Blood Pressure and Cardiovascular Prevention 1998;7(Number 4):156-167. Moore, MA. Hypertensive renal disease. Seminars in Hypertension. 1999;2:2-5. Jones, D, Basile, J, Cushman, W, Egan, BM, Ferrario, CM, Hill, M, Lackland, DT, Mensah, GA, Moore, MA, Ofili, E, Roccella, EJ, and Smith, R. Managing hypertension in the southeastern United States: applying the guidelines from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNCVI South). Amer J Med Sci 1999;318:357-364. Ferrario, CM, Moore, MA. Perseverar, en el tratamiento: un factor crucial en el control adecuado de la hipertensión. Medicina Clinica 2001;116(2):4-8. Moore, MA. Improving the managed care of hypertension with angiotensin II antagonists. Am J Med Sci 2002;323:25. Moore MA, Motley T, and Plumb K. The challenge of community cardiovascular disease: The Dan River Region Cardiovascular Health Initiative Program-DRchip. Ethnicity & Disease 2002; (4):S3-9-S3-95. Moore, MA. Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension. J Clin Hypertens 2003,5:137-144. Moore, MA. Cardiovascular Disease…a continuing threat to homeland defense. (Editorial ) J Clin Hypertens. 2003. Sep-Oct;5(5):350-1. Houston, MC, Besterman, WH, Ferrario CM, Moore MA, Basile J, Egan, B, Lackland, D, Hawkins, Ree J, Rogers P, Wise D, Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States: Part I: Am J Med Sci. 2005 (submitted-in revision) Besterman, W, Houston MC, Basile, J, Egan B, Ferrario, CM, Lackland D, Hawkins, RG, Reed J, Rogers, PH, Wise, D, Moore MA. Part II: Treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci (submitted –in revision) 2005. Moore, MA, Buckalew, Jr V, Burgess, R, Caruana, R, Harper, CC. Outpatient Hypertension Management: A Guide for the Physician Extender to Evaluate and Manage Hypertensive Outpatients. Editor and Major Contributing Author, Bowman Gray School of Medicine Press. 1980. Moore, MA. Outpatient Hypertension Management. Second Edition. 1980.
BOOK CHAPTERS:
Buckalew, Jr V, Moore, MA. Renal Tubular Dysfunction: Discussions in Patient Management, Chapters 3 & 4. Medical Review Publishing Company. 1979. Moore, MA. Renal Parenchymal Disease: Evaluation. Hypertension Primer. High Blood Pressure Research Council, American Heart Association. Izzo JL, Black HR, eds. Dallas 1993:265-267. Moore, MA. National High Blood Pressure Education Program – 20 Years of Achievement. Chapter 11, Assessing Program Achievements. National Heart, Lung, and Blood Institute. 1992.
MONOGRAPHS:
Moore, MA. Chronic Renal Failure. American Academy of Family Physicians. AAFP Home Study Self-Assessment. 1992. Moore, MA. Tailoring Treatment to Meet Individual Needs. African American Hypertension American Academy of Physician Assistants. 1994. Thornhill-Joynes, M, Moore, MA. Identifying Renal Disease in the African American Community: A Continuing Problem. 1995. Moore, MA. Renal Failure: A Complication Amplified in African Americans. Monograph on African American Hypertension for The International Society of Hypertension in Blacks. 1995.
LETTERS TO THE EDITOR:
Moore, MA, Phillippi P. Clonidine overdose. Lancet 1976;2:694.
INTERNET BASED EDUCATIONAL ACTIVITIES:
Learning Systems, Inc. Web Site, www.learningsystems.net, Danville, Virginia, February, 2000. Moore, MA. Speakers training program on the role of Angiotensin II in Cardiovascular Disease. Boron Lapore, Inc., www.boronlapore.com, Norfolk, Virginia, 2001. Moore, MA. Improving Patient Compliance. DRchip.NHLBI EDUC Extranet. 2002. Moore, MA. Strategies to Improve Health Care Provider Cardiovascular Disease Outcomes. DRchip NHLBI Extranet. September 2003.
MISCELLANEOUS
:
Moore, MA. Hypertension and renal arteriovenous malformations: a review, part I and II. Hypertension (non indexed publication)1975;2(5/6):21. Moore, MA. Hypertension and RAVF separate entities or cause and effect? Hypertension (non indexed publication) 1976;2:21-24. Moore, MA, Rufty AJ, Hamilton R, et al. Hypertension: Current State of Affairs. Official Publication of the North Carolina Heart Association. 1977, 1978, 1979. Peach, M, Jackson, TW Jr, Ayers, C, Miller, W, Moore, M, Camplong, L, Miller, J. Virginia Survey to Assess the Diagnosis, Treatment and Management of the Hypertensive Patient. Proceedings of the American Heart Association Annual Meeting, 1985. Contributing author of Physician's Office Management of Hypertension Component of Heart in the Health Site, American Heart Association, Dallas, Texas, 1986. Moore, MA. Research seeks answers to link between high blood pressure and chronic kidney failure. Medical News Report, 1990. Moore, MA. Epidemiology of Essential Hypertension. In: Original Submissions from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNCVI) U.S. Department of Health and Human Services. Public Health Services. NHLBI, February 1999;13-16. Moore, MA. Seminars in Hypertension Management 1999. 1977 Train Public Health Nurses in Hypertension Management Program. State of North Carolina Department of Health. 1982 Use of MK421 in Moderate to Severe Hypertension. Merck Pharmaceuticals. 1983 A Controlled, Double Blind Multi-clinic Study to Compare the Antihypertensive Effects of MK 421, plus Hydrochlorothiazide and Metoprolol plus Hydrochlorothiazide in Patients with Mild to Moderate Hypertension. Merck Pharmaceuticals. 1992 Modification of Diet in Renal Disease. Satellite Clinic Site with Nephrology Section, Bowman Gray School of Medicine. National Institutes of Health. 1994 A Prospective Open Label Randomized Comparison of Two Treatment Regimens: Cozaar- Hyzaar vs. Usual Care in Patients being Treated for Mild to Moderate Hypertension and Needing a Change in Therapy. (LETS Trial) Merck Pharmaceuticals. 1997 A Triple Blind, Parallel Study to Investigate the Effect of Losartan vs. Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy (LIFE)— United States. Merck Pharmaceuticals. 1998 A Dose Ranging, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Lanthanum Carbonate for Reduction of Serum Phosphorous in Chronic Renal Failure Patients Receiving Hemodialysis. Protocol LAM IV-204. Shire Laboratory. 2000 & 2001 Dan River Region Cardiovascular Health Initiative Program (DRchip) Program Development Grant. Danville Regional Health Foundation. 2001 DRchip: Cardiovascular Center of Excellence Grant. Consortium for Southeastern Hypertension Control. 2000 NHLBI Education, Dissemination & Utilization Center Project Contract. Dan River Cardiovascular Health Initiative Program (DRchip) National Heart Lung & Blood Institute.

Source: http://www.learning-systems.net/downloads/MAMCV02_25_05.pdf

113719_pj_23_(005_008).indd

 P h a r m a z i e u n d M e d i z i n · P h a r m a c i e e t m é d e c i n e Praxis Updates Pharmazie Neue Möglichkeit der hormonellen Notfallkontrazeption Eva Franz, Brigitte Frey Tirri, Isabelle Arnet Die europäische Arzneimittelbehörde EMA hat im Mai 2009 für ellaOne® (In-  Kupferspirale (IUD – intrauterine De- haltsstoff Ulipristalacetat, UPA) die Zulassung als No

Lebenslaufeichbaum1113

Prof. Dr. med. Michael H. R. Eichbaum Curriculum vitae Personalien Name: verheiratet mit Dr. med. Christine Eichbaum, geb. Loebel; eine Tochter (Katharina), einen Sohn (Julius) Schulischer Werdegang: Grundschule Universitärer Werdegang: Studium der Humanmedizin Ruprecht-Karls-Universität Heidelberg, Université de Paris VI III. Medizinisches Staatsexamen („gut“

Copyright © 2010-2014 Online pdf catalog